Evangelische Kliniken Gelsenkirchen GmbH
- Address
- Munckelstrasse 27, Altstadt, 45879 Gelsenkirchen, Germany
Evangelische Kliniken Gelsenkirchen GmbH - Breast Cancer Research Center
Evangelische Kliniken Gelsenkirchen GmbH is a distinguished clinical research center specializing in advanced early breast cancer treatment strategies. The institution focuses on developing personalized, marker-adjusted therapeutic approaches that aim to optimize treatment outcomes while potentially reducing treatment burden for patients with various breast cancer subtypes.
- Triple-negative early breast cancer (TNBC) with neoadjuvant immunotherapy combinations
- Hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer with CDK4/6 inhibitor strategies
- Personalized adjuvant therapy based on dynamic biomarker assessment and risk stratification
- Chemotherapy de-escalation approaches in intermediate-risk breast cancer populations
The center demonstrates particular expertise in conducting Phase III trials evaluating novel therapeutic combinations, including sacituzumab govitecan, pembrolizumab, abemaciclib, and ribociclib. Their research portfolio emphasizes the ADAPT (Adjuvant Dynamic marker-Adjusted Personalized Therapy) trial series, which represents a cutting-edge approach to individualizing breast cancer treatment based on clinical and genomic risk assessment. The institution's commitment to evaluating both treatment intensification and de-escalation strategies reflects a comprehensive approach to optimizing the therapeutic index in breast cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Evangelische Kliniken Gelsenkirchen GmbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | 2024-10-10 | 2024-11-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.